@kainvests · ranked 4 of 4 scored days
$IOVA And what is happiness if not moments like this, however long or short? Our girl reached $10. Today, some of you are no longer red after a very long couple of years. Let's make it last: no selling one share! Hopefully only the beginning, dream team. 🤍
$IOVA And what is happiness if not moments like this, however long or short? Our girl reached $10. Today, some of you are no longer red after a very long couple of years. Let's make it last: not selling one share! Hopefully, only the beginning, dream team. 🤍
$IOVA Iovance Biotherapeutics is once again being mentioned as a potential M&A target, this time for Johnson & Johnson and Pfizer: https://t.co/UjOsmmR4Rg We don't know whether Iovance is for sale, but we do know that it is on many big pharmas' radar. The thesis is simple:
$IOVA Brian Gastman gave such an extraordinary presentation yesterday: engaging, accurate, complete. The highlight? Lots of excitement about data coming soon and, most importantly, every indication and new generations. And he has the data, the insider information, that we lack.
$IOVA 🗞️Trump Administration Shift Puts This Corner of Biotech Back in Favor. “With the FDA’s hard-liners gone, investors are rushing back into rare-disease bets.” The article is mainly about rare disease biotech, but I think the broader point applies to biotech in general: a
$IOVA Iovance Biotherapeutics is once again being mentioned as a potential M&A target, this time for Johnson & Johnson and Pfizer: https://t.co/UjOsmmR4Rg We don't know whether Iovance is for sale, but we do know that it is on many big pharmas' radar. The thesis is simple:
$IOVA Iovance Biotherapeutics is now Trending #1 worldwide on StockTwits, the world's largest social network for investors and traders. More than 10M registered users. While the challenges and opportunities haven’t changed… Hell yeah, that’s our girl. Tomorrow @IovanceBio will
$IOVA Iovance Biotherapeutics is once again being mentioned as a potential M&A target, this time for Johnson & Johnson and Pfizer: https://t.co/UjOsmmR4Rg We don't know whether Iovance is for sale, but we do know that it is on many big pharmas' radar. The thesis is simple:
$IOVA 🗞️WCLC 2026 is on and we are already hearing some news from ongoing clinical trials on NSCLC. Below, we can see how Merck-Gilead’s EVOKE-03 did not meet the primary end point thanks to Dr. Stephen (and bavariaron on StockTwits). So far we see some promising early data as
$IOVA 🗞️WCLC 2026 is on and we are already hearing some news from ongoing clinical trials on NSCLC. Below, we can see how Merck-Gilead’s EVOKE-03 did not meet the primary end point thanks to Dr. Stephen (and bavariaron on StockTwits). So far we see some promising early data as
$IOVA 🗞️WCLC 2026 is on and we are already hearing some news from ongoing clinical trials on NSCLC. Below, we can see how Merck-Gilead’s EVOKE-03 did not meet the primary end point thanks to Dr. Stephen (and bavariaron on StockTwits). So far we see some promising early data as